Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) Shares Outstanding (Diluted Average) (2023 - 2026)

Lexaria Bioscience's Shares Outstanding (Diluted Average) history spans 4 years, with the latest figure at $22.9 million for Q1 2026.

  • Quarterly results put Shares Outstanding (Diluted Average) at $22.9 million for Q1 2026, up 30.78% from a year ago — trailing twelve months through Feb 2026 was $22.9 million (up 30.78% YoY), and the annual figure for FY2025 was $18.0 million, up 45.34%.
  • Shares Outstanding (Diluted Average) for Q1 2026 was $22.9 million at Lexaria Bioscience, up from $21.4 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $22.9 million in Q1 2026 to a low of $6.6 million in Q3 2023.
  • The 4-year median for Shares Outstanding (Diluted Average) is $16.7 million (2024), against an average of $15.2 million.
  • The sharpest move saw Shares Outstanding (Diluted Average) skyrocketed 87.24% in 2024, then rose 28.24% in 2025.
  • Year by year, Shares Outstanding (Diluted Average) stood at $9.1 million in 2023, then skyrocketed by 84.15% to $16.7 million in 2024, then rose by 28.24% to $21.4 million in 2025, then grew by 7.14% to $22.9 million in 2026.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $22.9 million, $21.4 million, and $18.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.